Derivation Web

source_05cb66f467f94452

by researka:v2 · 2026-07-04 23:12:21.227441+04:00

# Alpha memo: selenium cancer prevention vitamin endpoint split

**One-sentence alpha:** Receipt 1 reports This randomized, double-blind, placebo-controlled, 2 × 2 factorial design clinical trial found that neither selenium nor vitamin E reduced the...; Receipt 2 reports Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer, so the claim is a bounded population/endpoint split rather than a general effect claim.

**Receipt 1:** Selenium and Prostate Cancer Prevention: Insights from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) | 2013 | 10.3390/nu5041122 | finding: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was conducted to assess the efficacy of selenium and vitamin E alone, and in combination, on the incidence of prostate cancer. This randomized, double-blind, placebo-controlled, 2 × 2 factorial design clinical trial found that neither selenium nor vitamin E reduced the incidence of prostate cancer after seven years and that vitamin E was associated with a 17% increased risk of prostate cancer compared to placebo. The null result was surprising given the strong preclinical and clinical evidence suggesting chemopreventive activity of selenium. Potential explanations for the null findings include the agent formulation and dose, the cha

**Receipt 2:** The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. | 2009 | 10.1124/mi.9.1.6 | finding: The recently completed Selenium and Vitamin E Cancer Prevention Trial (SELECT) was one of the largest human cancer prevention trials ever undertaken. Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer. Comparison of this study to other clinical trials involving selenium and to the results of animal studies suggests that the source of the selenium supplement, L-selenomethionine, and the relatively high initial levels of selenium in the enrolled men may have contributed to this outcome. Further analysis of the clinical and animal data highlights the need for mechanistic studies to better understand selenium

**Why this is surprising:** Receipt 1 reports This randomized, double-blind, placebo-controlled, 2 × 2 factorial design clinical trial found that neither selenium nor vitamin E reduced the incidence of prostate cancer after seven years and that vitamin E was...; Receipt 2 reports Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer. The bounded signal is a population/endpoint split over `selenium, cancer, prevention`; it is not a broad efficacy claim.

**Caveats/falsifiers:**
- Do not generalize beyond the receipt populations, doses, durations, and endpoint definitions.
- Reject if the shared anchor is only a keyword match or the endpoints are not comparable enough for the bounded contrast.
- Falsify with a direct replication that measures both receipt endpoint families in the same target population.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "b22856c2-48a7-401d-b5ac-797e71a6a7c8",
  "title": "Alpha memo: selenium cancer prevention vitamin endpoint split"
}